As of 3:59pm ET
| +0.13 / +0.25%|
Cepheid operates as a molecular diagnostics company, which develops, manufactures, and markets fully-integrated systems for testing in the clinical market, as well as for application in the company's legacy industrial, biothreat, and partner markets. The company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. It operates through the GeneXpert and SmartCycler principal systems. The GeneXpert system integrates sample preparation in addition to deoxyribonucleic acid (DNA) amplification and detection. This system is designed for a broad range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. The company was founded by Thomas L. Gutshall, William McMillan, Kurt Petersen, Greg Kovacs, and M. Allen Northrup on March 4, 1996 and is headquartered in Sunnyvale, CA.
|John L. Bishop||Chairman & Chief Executive Officer|
|Warren C. Kocmond||President & Chief Operating Officer|
|Daniel E. Madden||Chief Financial & Principal Accounting Officer|
|David H. Persing||Class II Director & Chief Medical Officer|
|William E. Murray||Chief Privacy Officer, EVP & General Counsel|